Guangzhou Bio-gene Technology Co., Ltd
Clinical trials sponsored by Guangzhou Bio-gene Technology Co., Ltd, explained in plain language.
-
New CAR-T therapy targets lupus and arthritis in early trial
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target two proteins (CD19 and BCMA), for connective tissue diseases like lupus and rheumatoid arthritis. The goal is to see if it is safe and can control the disease. About 20 people will take part i…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 08:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis study tests a new treatment called CAR-T cell therapy for people with advanced colorectal cancer that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins (CDH17 and GUCY2C) found on cancer cells. The goal i…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 08:00 UTC
-
Engineered immune cells take on Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests a new treatment called B7H3 CAR-T cell therapy for people with advanced solid tumors that have a specific marker (B7H3). The therapy uses a patient's own immune cells, modified to better find and attack cancer cells. The main goals are to check safety and see if …
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 08, 2026 12:01 UTC